Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: The SEPIA-PCI Trial
- Author
- COHEN, Marc1 ; BHATT, Deepak L2 ; ALEXANDER, John H3 ; MONTALESCOT, Gilles4 ; BODE, Christoph5 ; HENRY, Timothy6 ; TAMBY, Jean-Francois7 ; SAAIMAN, Jan8 ; SIMEK, Stanislas9 ; DE SWART, Johannes10
[1] Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ, United States
[2] Cleveland Clinic, Cleveland, Ohio, United States
[3] Duke University Medical Center, Durham, NC, United States
[4] Hopital La Pitié Salpétrière, Paris, France
[5] University of Freiburg Medical Center, Freiburg, Germany
[6] Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, Minn., United States
[7] Sanofi-aventis, Bridgewater, NJ, United States
[8] Kuols River Private Hospital, Capetown, South Africa
[9] General University Hospital, Prague, Czech Republic
[10] Medical Center, Alkmaar, Netherlands - Source
Circulation (New York, N.Y.). 2007, Vol 115, Num 20, pp 2642-2651, 10 p ; ref : 23 ref
- CODEN
- CIRCAZ
- ISSN
- 0009-7322
- Scientific domain
- Cardiology, blood circulation, phlebology
- Publisher
- Lippincott Williams & Wilkins, Hagerstown, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Author keyword
- angioplasty anticoagulants coronary disease factor Xa revascularization
- Keyword (fr)
- Anticoagulant Appareil circulatoire pathologie Cardiopathie coronaire Dilatation instrumentale Etude double insu Otamixaban Revascularisation Voie percutanée Coagulation Factor Xa Enzyme Hydrolases Inhibiteur enzyme Peptidases Serine endopeptidases
- Keyword (en)
- Anticoagulant Cardiovascular disease Coronary heart disease Instrumental dilatation Double blind study Otamixaban Revascularization Percutaneous route Coagulation Factor Xa Enzyme Hydrolases Enzyme inhibitor Peptidases Serine endopeptidases
- Keyword (es)
- Anticoagulante Aparato circulatorio patología Cardiopatía coronaria Dilatación instrumental Estudio doble ciego Otamixabán Revascularización Vía percutánea Coagulation Factor Xa Enzima Hydrolases Inhibidor enzima Peptidases Serine endopeptidases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02F Cardiovascular system / 002B02F04 Vasodilator agents. Cerebral vasodilators
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B12 Cardiology. Vascular system / 002B12A Heart / 002B12A03 Coronary heart disease
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B12 Cardiology. Vascular system / 002B12B Blood and lymphatic vessels / 002B12B03 Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
- Discipline
- Cardiology. Circulatory system Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 18803922
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1161/CIRCULATIONAHA.106.653428 
https://dx.doi.org/10.1161/CIRCULATIONAHA.106.653428
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:33:\"10.1161\/CIRCULATIONAHA.106.653428\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:180:\"Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: The SEPIA-PCI Trial\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Circulation (New York, N.Y.)\";s:9:\"\u0000*\u0000stitle\";s:24:\"Circulation (N. Y. N.Y.)\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"115\";s:8:\"\u0000*\u0000issue\";s:2:\"20\";s:8:\"\u0000*\u0000spage\";s:4:\"2642\";s:8:\"\u0000*\u0000epage\";s:4:\"2651\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-7322\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"COHEN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Marc\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:15:\"BHATT, Deepak L\";i:1;s:17:\"ALEXANDER, John H\";i:2;s:19:\"MONTALESCOT, Gilles\";i:3;s:15:\"BODE, Christoph\";i:4;s:14:\"HENRY, Timothy\";i:5;s:20:\"TAMBY, Jean-Francois\";i:6;s:12:\"SAAIMAN, Jan\";i:7;s:16:\"SIMEK, Stanislas\";i:8;s:18:\"DE SWART, Johannes\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIRCAZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:180:\"Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: The SEPIA-PCI Trial\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:33:\"10.1161\/CIRCULATIONAHA.106.653428\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:180:\"Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: The SEPIA-PCI Trial\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Circulation (New York, N.Y.)\";s:9:\"\u0000*\u0000stitle\";s:24:\"Circulation (N. Y. N.Y.)\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"115\";s:8:\"\u0000*\u0000issue\";s:2:\"20\";s:8:\"\u0000*\u0000spage\";s:4:\"2642\";s:8:\"\u0000*\u0000epage\";s:4:\"2651\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-7322\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"COHEN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Marc\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:15:\"BHATT, Deepak L\";i:1;s:17:\"ALEXANDER, John H\";i:2;s:19:\"MONTALESCOT, Gilles\";i:3;s:15:\"BODE, Christoph\";i:4;s:14:\"HENRY, Timothy\";i:5;s:20:\"TAMBY, Jean-Francois\";i:6;s:12:\"SAAIMAN, Jan\";i:7;s:16:\"SIMEK, Stanislas\";i:8;s:18:\"DE SWART, Johannes\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIRCAZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:180:\"Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: The SEPIA-PCI Trial\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:33:\"10.1161\/CIRCULATIONAHA.106.653428\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:33:\"10.1161\/CIRCULATIONAHA.106.653428\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:180:\"Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: The SEPIA-PCI Trial\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Circulation (New York, N.Y.)\";s:9:\"\u0000*\u0000stitle\";s:24:\"Circulation (N. Y. N.Y.)\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"115\";s:8:\"\u0000*\u0000issue\";s:2:\"20\";s:8:\"\u0000*\u0000spage\";s:4:\"2642\";s:8:\"\u0000*\u0000epage\";s:4:\"2651\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-7322\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"COHEN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Marc\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:15:\"BHATT, Deepak L\";i:1;s:17:\"ALEXANDER, John H\";i:2;s:19:\"MONTALESCOT, Gilles\";i:3;s:15:\"BODE, Christoph\";i:4;s:14:\"HENRY, Timothy\";i:5;s:20:\"TAMBY, Jean-Francois\";i:6;s:12:\"SAAIMAN, Jan\";i:7;s:16:\"SIMEK, Stanislas\";i:8;s:18:\"DE SWART, Johannes\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIRCAZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:180:\"Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: The SEPIA-PCI Trial\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:33:\"10.1161\/CIRCULATIONAHA.106.653428\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:180:\"Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: The SEPIA-PCI Trial\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Circulation (New York, N.Y.)\";s:9:\"\u0000*\u0000stitle\";s:24:\"Circulation (N. Y. N.Y.)\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"115\";s:8:\"\u0000*\u0000issue\";s:2:\"20\";s:8:\"\u0000*\u0000spage\";s:4:\"2642\";s:8:\"\u0000*\u0000epage\";s:4:\"2651\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-7322\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"COHEN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Marc\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:15:\"BHATT, Deepak L\";i:1;s:17:\"ALEXANDER, John H\";i:2;s:19:\"MONTALESCOT, Gilles\";i:3;s:15:\"BODE, Christoph\";i:4;s:14:\"HENRY, Timothy\";i:5;s:20:\"TAMBY, Jean-Francois\";i:6;s:12:\"SAAIMAN, Jan\";i:7;s:16:\"SIMEK, Stanislas\";i:8;s:18:\"DE SWART, Johannes\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIRCAZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:180:\"Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: The SEPIA-PCI Trial\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:33:\"10.1161\/CIRCULATIONAHA.106.653428\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:180:\"Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: The SEPIA-PCI Trial\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Circulation (New York, N.Y.)\";s:9:\"\u0000*\u0000stitle\";s:24:\"Circulation (N. Y. N.Y.)\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"115\";s:8:\"\u0000*\u0000issue\";s:2:\"20\";s:8:\"\u0000*\u0000spage\";s:4:\"2642\";s:8:\"\u0000*\u0000epage\";s:4:\"2651\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-7322\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"COHEN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Marc\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:15:\"BHATT, Deepak L\";i:1;s:17:\"ALEXANDER, John H\";i:2;s:19:\"MONTALESCOT, Gilles\";i:3;s:15:\"BODE, Christoph\";i:4;s:14:\"HENRY, Timothy\";i:5;s:20:\"TAMBY, Jean-Francois\";i:6;s:12:\"SAAIMAN, Jan\";i:7;s:16:\"SIMEK, Stanislas\";i:8;s:18:\"DE SWART, Johannes\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIRCAZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:180:\"Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: The SEPIA-PCI Trial\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
